Zealand Pharma's experimental obesity treatment, ZEL-110, delivered only 5.8% average weight loss after 24 weeks in a Phase 2 trial, falling short of expectations. The underperformance triggered a 22% drop in the company’s stock and raised concerns about the viability of next-generation GLP-1 candidates.
- ZEL-110 achieved 5.8% average weight loss in 24 weeks, falling short of 10% benchmark
- Phase 2 trial involved 240 patients with obesity or overweight and comorbidities
- Zealand Pharma’s stock (ZEL) dropped 22% post-results announcement
- Broader biotech sector saw declines, with XLV falling 1.7%
- Investor confidence in next-gen GLP-1/GIP dual agonists has weakened
- High expectations for metabolic disease drugs now face heightened scrutiny
Zealand Pharma’s investigational obesity drug, ZEL-110, underperformed in a recent Phase 2 clinical trial, delivering an average weight loss of 5.8% after 24 weeks of treatment—well below the 10% threshold seen in leading GLP-1 therapies. The trial included 240 adult patients with obesity or overweight and high cardiometabolic risk, and the results were presented at a medical conference in late February 2026, prompting immediate market reaction. The disappointing outcome underscores the growing challenges in the highly competitive weight-loss drug space, where investors have priced in high expectations for novel mechanisms. ZEL-110, a dual agonist targeting both GLP-1 and GIP receptors, was expected to offer improved efficacy and tolerability over existing options. However, its modest weight-loss profile suggests it may not achieve a differentiated advantage, particularly given the strong performance of products like tirzepatide and semaglutide. The stock, traded under the ticker ZEL on Nasdaq, dropped 22% in after-hours trading following the announcement, erasing approximately $1.3 billion in market value. This sell-off has rippled through the broader biotech sector, with the XBI ETF (XLV) declining 1.7% and related healthcare stocks experiencing renewed caution. Analysts now question the feasibility of late-stage development for other dual-agonist candidates in the pipeline. Investor sentiment toward late-stage obesity therapeutics has turned cautious, with implications for companies advancing similar mechanisms. The result also affects biotech valuation models, as expected clinical milestones become harder to predict. Given the high R&D costs and long development timelines, setbacks like this increase the risk profile for emerging players in metabolic disease therapeutics.